Study of Danicamtiv for Genetic and Familial Dilated Cardiomyopathy
This study is testing an investigational medication called danicamtiv for people with genetic and familial dilated cardiomyopathy (DCM). DCM is a condition where the heart muscle weakens and enlarges, making it harder to pump blood. Currently, there are no approved drugs specifically for genetic or familial DCM. Researchers want to see how well danicamtiv works compared to a placebo (a sugar pill with no medicine) and how safe it is. You might be able to join if you are 18 or older, have a diagnosis of DCM due to specific genetic changes or family history, and have stable symptoms. The study will look at changes in your heart function and exercise ability after 26 weeks.
- Study design
- This study involves 332 participants who will receive either danicamtiv or a placebo twice daily for up to 26 weeks.
- What's involved
- Participants will take danicamtiv or a placebo twice daily for up to 26 weeks. Specific visits or procedures are not detailed.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoints are measured at 26 weeks, indicating a follow-up period of at least that long.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
At a glance
Conditions
Where it's being run
78 sites across 31 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Part 1: Change from Baseline (Day 1) to Week 26 in left atrial function index in Cohort 126 weeks
- Part 2: Change from Baseline (Day 1) to Week 26 in peak VO2 in Cohort 126 weeks